Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.The ODD in Japan adds to other important designations: the SAKIGAKE designation by Japan's MHLW in March 2023, the Orphan Drug ...